Boehringer Ingelheim, Eli Lilly’s Jardiance nabs approval in Europe for chronic kidney disease

Boehringer In­gel­heim and Eli Lil­ly said Jar­diance re­ceived ap­proval in Eu­rope as a treat­ment for chron­ic kid­ney dis­ease in adults, with the FDA’s de­ci­sion on the drug for that in­di­ca­tion ex­pect­ed to come this year.

Jar­diance, or em­pagliflozin, has al­ready been ap­proved by the Eu­ro­pean Com­mis­sion for type 2 di­a­betes and heart fail­ure. The com­pa­nies said Tues­day that the ap­proval will im­prove care for the more than 47 mil­lion peo­ple in the EU with chron­ic kid­ney dis­ease, or CKD, and can help low­er the risk of all-cause hos­pi­tal­iza­tion for CKD pa­tients.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN